Comparative Pharmacology
Head-to-head clinical analysis: HETRAZAN versus PIPERAZINE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETRAZAN versus PIPERAZINE CITRATE.
HETRAZAN vs PIPERAZINE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Category C
Category C
Anthelmintic
Anthelmintic